Epica International, Inc.

Epica International, Inc. specializes in advanced medical imaging and robotic systems, providing innovative solutions that enhance precision and automation in healthcare and industrial environments. Founded in 2013, Epica International, Inc. is headquartered in San Clemente, US.

The company focuses on developing advanced imaging technologies and robotics, and it has been involved in 11 deals. The latest funding round occurred in September 2024, where the company raised USD 0. 610 mn. The company's CEO is Frank D'amelio, with Joseph Soto also in leadership roles.

The founder, Greg Stoutenburgh, has a history of innovation in the technology sector. Epica International specializes in advanced medical imaging platforms and robotic systems designed to enhance precision and automation in both medical and industrial settings. Their core offerings include a mobile, multi-modality imaging platform that integrates HDVI CT, fluoroscopy, and digital radiography, all of which are FDA 510(k) cleared for human use and carry CE Mark certification. This state-of-the-art platform addresses critical needs in both human and veterinary healthcare, providing high-resolution imaging solutions for hospitals, clinics, and veterinary practices.

In addition, Epica International's Roboticom division develops precision robotics for tasks such as sanding, polishing, cutting, and sculpting, primarily serving the manufacturing and orthotics/prosthetics sectors. The company's products are marketed to customers across North America, Europe, and Asia, allowing them to effectively cater to varied healthcare and industrial needs around the globe. Epica International conducts its business through a model that includes direct sales of its advanced imaging and robotic products to healthcare providers and industrial end-users. The company generates revenue through transactional sales of its flagship products, such as the mobile imaging platforms and various robotic automation solutions.

Engagements with clients typically involve direct purchase agreements, with institutions investing in individual units or comprehensive packages tailored to their operational needs. Additional revenue may be derived from service agreements and maintenance contracts, ensuring customers have ongoing support and upgrades for their purchased systems. The sales structure fosters strong relationships with hospitals, veterinary clinics, and manufacturing facilities, reinforcing Epica International as a key provider in both medical and industrial sectors. In September 2024, Epica International, Inc.

raised USD 13. 5 million in venture debt funding from new investor Avenue Capital Group. The company plans to utilize this funding to support its growth and expansion in medical technology. Upcoming product launches include enhancements to their imaging platforms, aimed for release in 2025, as well as new robotic solutions designed for industrial applications.

Geographically, Epica International aims to expand its reach within Europe and Asia by 2026, targeting specific markets with tailored solutions to meet local needs.